REFERENCES
1.
Warfel, JM, Edwards, KM. Pertussis vaccines and the challenge of inducing durable immunity. Current Opinion in Immunology
2015; 35: 48–54.
2.
van Hoek, AJ, et al.
The burden of disease and health care use among pertussis cases in school aged children and adults in England and Wales; a patient survey. PLoS ONE
2014; 9: e111807.
3.
Schellekens, J, von König, C-HW, Gardner, P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatric Infectious Disease Journal
2005; 24: S19–24.
4.
Campbell, H, et al.
Accelerating control of pertussis in England and Wales. Emerging Infectious Diseases
2012; 18: 38–47.
5.
Miller, E. Overview of recent clinical trials of acellular pertussis vaccines. Biologicals
1999; 27: 79–86.
6.
Wendelboe, AM, et al.
Duration of immunity against pertussis after natural infection or vaccination. Pediatric Infectious Disease Journal
2005; 24: S58–61.
7.
Tartof, SY, et al.
Waning immunity to pertussis following 5 doses of DTaP. Pediatrics
2013; 131: e1047–1052.
8.
Clark, TA. Changing pertussis epidemiology: everything old is new again. Journal of Infectious Diseases
2014; 209: 978–981.
9.
Skoff, TH, Martin, SW. Impact of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccinations on reported pertussis cases among those 11 to 18 years of age in an era of waning pertussis immunity: a follow-up analysis. JAMA Pediatrics
2016; 170: 453–458.
10.
World Health Organization. Pertussis vaccines: WHO position paper – August 2015. Weekly Epidemiological Record
2015; 90: 433–460.
11.
Warfel, JM, Zimmerman, LI, Merkel, TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proceedings of the National Academy of Sciences USA
2014; 111: 787–792.
12.
Amirthalingam, G, et al.
Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet
2014; 384: 1521–1528.
13.
Dabrera, G, et al.
A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012–2013. Clinical Infectious Diseases
2015; 60: 333–337.
14.
Tan, T, Trindade, E, Skowronski, D. Epidemiology of pertussis. Pediatric Infectious Disease Journal
2005; 24: S10–18.
15.
Public Health England. Laboratory confirmed pertussis in England: data to end-August 2014. Health Protection Report
2014; 8: 2–5.
16.
Wiley, KE, et al.
Sources of pertussis infection in young infants: a review of key evidence informing targeting of the cocoon strategy. Vaccine
2013; 31: 618–625.
17.
De, Serres G, et al.
Morbidity of pertussis in adolescents and adults. Journal of Infectious Disease
2000; 182: 174–179.
18.
Pascual, FB, et al.
Outbreak of pertussis among healthcare workers in a hospital surgical unit. Infection Control and Hospital Epidemiology
2006; 27: 546–552.
19.
Baugh, V, McCarthy, N. Outbreak of Bordetella pertussis among oncology nurse specialists. Occupational Medicine
2010; 60: 401–405.
20.
Bassinet, L, et al.
Nosocomial pertussis outbreak among adult patients and healthcare workers. Infection Control and Hospital Epidemiology
2004; 25: 995–997.
21.
Wright, SW, Decker, MD, Edwards, KM. Incidence of pertussis infection in healthcare workers. Infection Control and Hospital Epidemiology
1999; 20: 120–123.
22.
Cunegundes, KSA, et al.
Bordetella pertussis infection in paediatric healthcare workers. Journal of Hospital Infection
2015; 90: 163–166.
23.
Riffelmann, M, et al.
Antibodies to pertussis antigens in pediatric health care workers. Pediatric Infectious Disease Journal
2002; 21: 381–383.
24.
Health Protection Agency. Public Health Management of Pertussis. London: Health Protection Agency, 2012.
25.
Bechini, A, et al.
Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations. Vaccine
2012; 30: 5179–5190.
26.
Hope, K, et al.
Pertussis vaccination in child care workers: room for improvement in coverage, policy and practice. BMC Pediatrics
2012; 12: 98.
27.
Hosmer, DW, Lemeshow, S. Applied Logistic Regression. New York: John Wiley & Sons, 2001.
28.
Breslow, NE. Statistics in epidemiology: the case-control study. Journal of the American Statistical Association
1996; 91: 14–28.
29.
Lavine, JS, King, AA, Bjornstad, ON. Natural immune boosting in pertussis dynamics and the potential for long-term vaccine failure. Proceedings of the National Academy of Sciences USA
2011; 108: 7259–7264.
30.
Bisgard, KM, et al.
Infant pertussis. Pediatric Infectious Disease Journal
2004; 23: 985–989.
31.
Wendelboe, AM, et al.
Transmission of Bordetella pertussis to young infants. Pediatric Infectious Disease Journal
2007; 26: 293–299.
32.
de Greeff, SC, et al.
Pertussis disease burden in the household: how to protect young infants. Clinical Infectious Diseases
2010; 50: 1339–1345.
33.
Sheridan, SL, et al.
Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology. Expert Review of Vaccines
2014; 13: 1081–1106.
34.
Health Protection Agency. Laboratory-confirmed cases of pertussis reported to the enhanced pertussis surveillance programme (England and Wales). Health Protection Report
2012; 6: 4–7.
35.
Lavine, JS, et al.
Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine. Vaccine
2012; 30: 544–551.
36.
Quinn, H, McIntyre, P. The impact of adolescent pertussis immunization, 2004–2009: lessons from Australia. Bulletin of the World Health Organization
2011; 89: 666–674.